Aptevo Therapeutics Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-6.02 | $-5.31 | +11.8% | Beat |
| Q22026 FY2026 | $-6.01 | $-99.99 | -1563.7% | Miss |
| Q12026 FY2026 | $-5.60 | $-6.41 | -14.5% | Miss |
| Q42025 FY2025 | $-8.09 | — | — | Miss |
Back to APVO overview · APVO holders · APVO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.